BRPI1008392A2 - Isolated monocyte populations and related therapeutic applications - Google Patents

Isolated monocyte populations and related therapeutic applications

Info

Publication number
BRPI1008392A2
BRPI1008392A2 BRPI1008392-8A BRPI1008392A BRPI1008392A2 BR PI1008392 A2 BRPI1008392 A2 BR PI1008392A2 BR PI1008392 A BRPI1008392 A BR PI1008392A BR PI1008392 A2 BRPI1008392 A2 BR PI1008392A2
Authority
BR
Brazil
Prior art keywords
therapeutic applications
related therapeutic
monocyte populations
isolated monocyte
isolated
Prior art date
Application number
BRPI1008392-8A
Other languages
Portuguese (pt)
Inventor
Martin Friedlander
Matthew R Ritter
Stacey K Moreno
Mohammad A El-Kalay
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI1008392A2 publication Critical patent/BRPI1008392A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1497—Particle shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008392-8A 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications BRPI1008392A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20817309P 2009-02-20 2009-02-20
US28324409P 2009-11-30 2009-11-30
PCT/US2010/000477 WO2010096177A1 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Publications (1)

Publication Number Publication Date
BRPI1008392A2 true BRPI1008392A2 (en) 2015-08-25

Family

ID=42634163

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008392-8A BRPI1008392A2 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Country Status (11)

Country Link
EP (1) EP2398900A4 (en)
JP (1) JP2012518407A (en)
KR (1) KR20110123778A (en)
CN (1) CN102317446A (en)
AU (1) AU2010216374A1 (en)
BR (1) BRPI1008392A2 (en)
CA (1) CA2752679A1 (en)
EA (1) EA201190109A1 (en)
MX (1) MX2011008826A (en)
WO (1) WO2010096177A1 (en)
ZA (1) ZA201105869B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2999479B1 (en) * 2013-05-22 2021-01-06 Yeda Research and Development Co., Ltd. Human monocyte sub-population for treatment of eye diseases and disorders
KR101668462B1 (en) * 2015-02-26 2016-10-24 충북대학교 산학협력단 Pharmaceutical Composition for Preventing or Treating a Glaucoma Comprising Blood Components as Active Ingredients
FR3084463B1 (en) * 2018-07-30 2023-04-21 Francais Du Sang Ets METHOD FOR ANALYZING PLATELETS FROM A BLOOD SAMPLE
CN114441419B (en) * 2022-01-29 2022-11-22 杭州翔宇医学检验实验室有限公司 Flow type gate looping method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CA2556018A1 (en) * 2004-02-11 2005-09-09 Aldagen, Inc. Stem cell populations and methods of use
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
US9089509B2 (en) * 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration

Also Published As

Publication number Publication date
EP2398900A1 (en) 2011-12-28
ZA201105869B (en) 2012-10-31
WO2010096177A1 (en) 2010-08-26
EP2398900A4 (en) 2012-08-22
AU2010216374A1 (en) 2011-08-18
EA201190109A1 (en) 2012-07-30
CA2752679A1 (en) 2010-08-26
KR20110123778A (en) 2011-11-15
CN102317446A (en) 2012-01-11
MX2011008826A (en) 2011-11-02
JP2012518407A (en) 2012-08-16

Similar Documents

Publication Publication Date Title
NL350111I2 (en) fenpicoxamid and prothioconazole
BRPI1010881A2 (en) triazine derivatives and their therapeutic applications.
BRPI1004907A2 (en) main unit and subordinate unit
BRPI1010882A2 (en) triazine derivatives and their therapeutic applications.
IT1400767B1 (en) MICROSYSTEM
BR112012007861A2 (en) medical devices and their pumps
BR112012001023A2 (en) extruder
DK2252688T3 (en) SYNTHETIC PHOSPHODIESTS-OLIGONUCLEOTIDES AND THERAPEUTIC APPLICATIONS THEREOF
DK2274619T3 (en) MILK DISEASES AND APPLICATIONS THEREOF
FR2964937B1 (en) TRIPORATOR AND TRIPORATOR DIRECTION
BRPI1015435A2 (en) Extruded particles
BRPI1011318A2 (en) triazine derivatives and their therapeutic applications
FI20090218A0 (en) Subwoofer structure
BRPI1008392A2 (en) Isolated monocyte populations and related therapeutic applications
BRPI1010720A2 (en) article
EP2440055A4 (en) Styryl-triazine derivatives and their therapeutical applications
UA20209S (en) HYPERTHERMOTHERAPEUTIC CHAIR
FI20096190A (en) research unit
SE0900379L (en) legrests
ES1071902Y (en) THERMOSOLDING AND PRECORT MECHANISM
UA20208S (en) HYPERTHERMOTHERAPEUTIC CHAIR
BRPI0924006A2 (en) structure
TH97629B (en) chair
TH123099B (en) The replaced dihydropyrazolone and its uses
ES1071143Y (en) HOSPITAL CAMISON

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.